Cerebrolysin for Stroke Recovery: The Evidence

Cerebrolysin

1,879 patients

A meta-analysis of nine randomized controlled trials found that cerebrolysin improved neurological outcomes at day 30 compared to placebo in acute ischemic stroke patients.

Bornstein et al., Neurological Sciences, 2018

Bornstein et al., Neurological Sciences, 2018

View as image

Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue through a standardized biotechnological process. It has been used clinically for neurological conditions in over 50 countries for decades, primarily in Europe and Asia, though it has never received FDA approval in the United States. The interest in cerebrolysin for stroke recovery rests on a specific pharmacological rationale: the peptide mixture mimics the activity of endogenous neurotrophic factors like BDNF, GDNF, and NGF, which are critical for neuronal survival, plasticity, and repair after ischemic brain injury.

Brainin et al. described cerebrolysin as a "multi-target drug for recovery after stroke" in a 2018 review, noting that unlike single-target neuroprotective agents that have repeatedly failed in stroke trials, cerebrolysin's pleiotropic mechanism engages multiple recovery pathways simultaneously.^[1] The evidence base includes nine randomized controlled trials, two large landmark studies (CASTA and CARS), and a meta-analysis pooling 1,879 patients. The results are positive but nuanced, with clearer benefits in specific patient subgroups than in unselected populations.

This article sits within a broader examination of cerebrolysin's clinical evidence. For its use in cognitive decline, see cerebrolysin for vascular dementia. For other neurological applications, see our articles on cerebrolysin and traumatic brain injury and how cerebrolysin works at the molecular level.

What Cerebrolysin Contains

Cerebrolysin is not a single peptide. It is a standardized preparation containing a defined mixture of neurotrophic peptides (approximately 25% by weight) and free amino acids (approximately 75%) derived from purified porcine brain proteins through controlled enzymatic proteolysis. The peptide fraction contains fragments that mimic the activity of several endogenous neurotrophic factors.^[5]

Masliah et al. characterized the pharmacological profile in 2012, demonstrating that cerebrolysin activates signaling pathways associated with BDNF (brain-derived neurotrophic factor), GDNF (glial cell-derived neurotrophic factor), CNTF (ciliary neurotrophic factor), and NGF (nerve growth factor).^[5] These factors promote neuronal survival, axonal growth, synaptic formation, and neurogenesis. The peptide fragments in cerebrolysin are small enough to cross the blood-brain barrier, which is a critical advantage over administering full-length neurotrophic factor proteins, which cannot reach the brain through peripheral administration.

Stepanichev et al. showed in 2017 that cerebrolysin modulates the NGF system in aging rat brains, increasing both NGF protein levels and TrkA receptor expression in the hippocampus and cortex.^[7] This is relevant to stroke recovery because neurotrophic factor levels decline with age, and older patients (who are most likely to have strokes) have a reduced endogenous capacity for neural repair.

The CASTA Trial: 1,070 Patients in Asia

The Cerebrolysin Acute Stroke Treatment in Asia (CASTA) trial, published by Heiss et al. in 2012, was the largest single randomized trial of cerebrolysin in stroke.^[3] It enrolled 1,070 patients with acute ischemic hemispheric stroke within 12 hours of symptom onset. Patients received either 30 mL cerebrolysin or placebo (saline) as a daily intravenous infusion for 10 days, in addition to standard care including aspirin.

The primary endpoint, a global statistical test combining four outcome measures at day 90, showed no statistically significant difference between cerebrolysin and placebo in the overall population. This result was widely interpreted as a negative trial.

However, a pre-specified subgroup analysis stratified by stroke severity revealed a different picture. In patients with severe strokes (NIHSS >12), cerebrolysin showed a strong trend toward benefit. The cumulative 90-day mortality in this subgroup was 10.5% with cerebrolysin compared to 20.2% with placebo.^[3] The finding suggests that cerebrolysin's neurotrophic effects may be most relevant when the brain damage is substantial enough that endogenous repair mechanisms are overwhelmed.

The CASTA trial was designed using the framework of a 2009 protocol paper by Hong et al., which established the rationale for testing cerebrolysin specifically in Asian stroke populations given the high incidence of ischemic stroke and the established clinical use of cerebrolysin across Asia.^[4]

The CARS Trials: Motor Function Recovery

The Cerebrolysin and Recovery after Stroke (CARS) program consisted of two identical randomized, placebo-controlled, double-blind studies (CARS-1 and CARS-2) focused specifically on motor function recovery during early rehabilitation. Treatment with 30 mL cerebrolysin once daily for 21 days (longer than the CASTA 10-day protocol) was initiated 24 to 72 hours after stroke onset, and all patients participated in a standardized rehabilitation program.

The combined analysis showed cerebrolysin superiority over placebo on the primary outcome, the Action Research Arm Test (ARAT) score at day 90. The ARAT measures fine motor coordination, grasp, grip, and pinch functions of the affected upper limb. This is a clinically meaningful endpoint because upper extremity motor recovery is one of the most important determinants of post-stroke functional independence.^[1]

The CARS trials differed from CASTA in two important ways: the treatment duration was longer (21 days vs. 10 days), and the endpoint focused specifically on motor function during rehabilitation rather than global neurological status. These design choices may explain why CARS showed clearer benefits than CASTA.

Meta-Analysis: Pooling Nine Trials

Bornstein et al. published a meta-analysis in 2018 pooling data from nine randomized controlled trials with a total of 1,879 patients, providing the most comprehensive assessment of cerebrolysin in acute ischemic stroke.^[2]

The key findings:

Cerebrolysin showed statistically significant superiority over placebo on the NIHSS (National Institutes of Health Stroke Scale) at day 30 (p < 0.0001). The number needed to treat (NNT) for a clinically relevant neurological improvement was 7.7, meaning that for every 7 to 8 patients treated, one additional patient achieved meaningful recovery beyond what would have occurred with standard care alone.^[2]

Safety was comparable to placebo across all nine trials. The incidence of adverse events, serious adverse events, and mortality did not differ between cerebrolysin and placebo groups. This is a notable finding because many previous neuroprotective drug candidates for stroke were abandoned due to safety concerns at effective doses.

The meta-analysis confirmed the pattern from CASTA: cerebrolysin's benefits were most pronounced in patients with moderate to severe strokes. Patients with mild strokes (low baseline NIHSS) showed less separation from placebo, likely because their endogenous recovery capacity was sufficient without pharmacological augmentation.

How Cerebrolysin Supports Stroke Recovery

Rejdak et al. reviewed the neurotrophic factor modulation by cerebrolysin in 2023, synthesizing evidence from stroke, dementia, and TBI studies.^[6] The mechanisms relevant to stroke recovery include:

Neuroprotection in the acute phase. During the first hours to days after stroke, cerebrolysin's neurotrophic peptides activate survival signaling through the PI3K/AKT and GSK3-beta pathways, reducing apoptotic cell death in the ischemic penumbra (the brain tissue surrounding the stroke core that is damaged but potentially salvageable).

Neuroplasticity during recovery. In the weeks following stroke, cerebrolysin promotes axonal sprouting, dendritic remodeling, and synaptogenesis. These processes allow surviving neurons to form new connections that compensate for lost neural circuits. The CARS trial results, showing improved motor function at day 90, are consistent with this mechanism.

Neurogenesis. Cerebrolysin stimulates the proliferation and differentiation of neural progenitor cells in the subventricular zone, the brain's endogenous stem cell niche. New neurons migrate to damaged areas and integrate into existing circuits, contributing to long-term functional recovery.^[5]

Anti-inflammatory effects. Cerebrolysin reduces microglial activation and the production of pro-inflammatory cytokines in the peri-infarct region. Post-stroke inflammation exacerbates tissue damage and impairs recovery; modulating this response supports a more favorable environment for neural repair.

Limitations and Open Questions

The cerebrolysin stroke evidence has genuine limitations that should be weighed alongside the positive findings.

The CASTA trial, the largest single study, was technically negative on its primary endpoint. The subgroup finding of mortality reduction in severe strokes was from a post hoc analysis, which carries a higher risk of spurious results. A prospective trial specifically enrolling severe stroke patients would be needed to confirm this signal.

The pooled meta-analysis was based on nine trials, but several were relatively small and conducted in different healthcare systems with different standards of stroke care. Heterogeneity in baseline stroke severity, time to treatment, concomitant therapies, and outcome measures complicates interpretation.

Cerebrolysin requires intravenous administration, which limits its use to hospital settings and the early post-stroke period. There is no oral formulation.

The drug is not approved by the FDA and is not part of major American or European stroke treatment guidelines, though it is included in treatment recommendations in several Asian and Eastern European countries. A 2023 Cochrane review of cerebrolysin for acute ischemic stroke concluded that while the drug appears safe, the certainty of evidence for efficacy remains low to moderate.

The mechanism of action, while supported by preclinical data, involves a complex mixture of peptides whose individual contributions to clinical effects are incompletely characterized. This makes it harder to optimize dosing, timing, and patient selection compared to single-molecule drugs.

The Bottom Line

Cerebrolysin demonstrates a consistent signal of benefit in stroke recovery across multiple randomized trials, particularly in patients with moderate to severe strokes. The meta-analysis of nine trials found a number needed to treat of 7.7 for clinically meaningful improvement, with safety comparable to placebo. The largest single trial (CASTA) was negative on its primary endpoint but showed suggestive mortality reduction in severe strokes. The CARS trials showed clear motor function benefits during rehabilitation. The drug remains unapproved in the US, and the evidence base, while positive, has limitations in trial design and certainty that preclude definitive conclusions.

Frequently Asked Questions

What is cerebrolysin used for in stroke?

Cerebrolysin is used as an adjunctive treatment during the acute and early recovery phase of ischemic stroke. It is administered intravenously at 30 mL daily for 10 to 21 days, typically starting within 24 to 72 hours of stroke onset. A meta-analysis of nine randomized trials with 1,879 patients found it improved neurological scores at day 30 compared to placebo, with a number needed to treat of 7.7 for clinically meaningful improvement (Bornstein et al., 2018).

Does cerebrolysin help with stroke recovery?

The evidence shows a consistent positive signal, particularly for motor function recovery and in patients with moderate to severe strokes. The CARS trials demonstrated cerebrolysin superiority over placebo on the Action Research Arm Test at day 90. However, the largest single trial (CASTA, 1,070 patients) was negative on its primary endpoint in the overall population, though it showed potential mortality reduction in severe stroke patients. The benefits appear most relevant when brain damage overwhelms endogenous repair capacity.

Is cerebrolysin FDA approved?

No. Cerebrolysin is not approved by the US Food and Drug Administration and is not included in American Stroke Association guidelines. It is approved and used clinically in over 50 countries, primarily in Europe, Asia, and Latin America. The lack of FDA approval reflects both regulatory pathway considerations and the fact that the evidence, while positive, does not yet meet the level of certainty that US regulators require for stroke treatments.

How does cerebrolysin work in the brain after a stroke?

Cerebrolysin contains peptide fragments that mimic endogenous neurotrophic factors including BDNF, GDNF, CNTF, and NGF. After stroke, these peptides activate survival signaling (PI3K/AKT pathway) to reduce cell death in salvageable brain tissue, promote axonal sprouting and new synapse formation to rebuild neural circuits, stimulate neurogenesis in the brain's stem cell niches, and reduce harmful inflammation around the stroke site (Masliah et al., 2012; Rejdak et al., 2023).

What were the results of the CASTA cerebrolysin trial?

The CASTA trial enrolled 1,070 acute ischemic stroke patients across Asia. The primary endpoint (a global test combining four measures at day 90) showed no significant difference between cerebrolysin and placebo overall. However, in patients with severe strokes (NIHSS score above 12), 90-day mortality was 10.5% with cerebrolysin versus 20.2% with placebo. The safety profile was comparable to placebo. The trial was published by Heiss et al. in Stroke in 2012.

Is cerebrolysin safe for stroke patients?

Across nine randomized controlled trials with 1,879 patients, cerebrolysin's safety profile was comparable to placebo. The meta-analysis by Bornstein et al. found no significant increase in adverse events, serious adverse events, or mortality with cerebrolysin treatment. The most common side effects are mild injection site reactions and dizziness. This favorable safety profile distinguishes cerebrolysin from many neuroprotective drug candidates that were abandoned due to toxicity at therapeutic doses.